Hillerdal Gunnar, Koyi Hirsh
Department of Respiratory Medicine, Regional Hospital, Gavle, Sweden.
Department of Respiratory Medicine an Allergy, Karolinska University Hospital, Stockholm, Sweden.
J Thorac Dis. 2020 Jul;12(7):3524-3528. doi: 10.21037/jtd-19-4082.
Endobronchial lung volume reduction (EBVR) with one-way valves introduced into the most diseased lobe of the lung is a non-invasive method to improve lung function in patients with severe heterogenous emphysema. The problem is to select the right patients for the procedure. Furthermore, the long-term effects have not been reported in most studies.
EBVR was performed in 35 patients with severely handicapping emphysema and with one radiologically clearly enlarged (at least 125%) target lung lobe and clearly visible and complete interlobar fissures on CT. Most of the successful survivors have then been followed for five years.
Five (14%) were primary failures (defined as less than 15% increase of FEV) and 10 (28%) were secondary failures (the valves were coughed up or removed for some reason). In the 21 successful l patients, the improvement of FEV was in the mean 59%. Over the years, FEV gradually decreased but was still higher 5 years later than initially. Of the successful group, 76% were still alive after 5 years, while only 50% were in the refused or failed groups.
With careful selection of patients remarkably good results in lung function can be achieved, and these improvements will last for years though slowly decrease. In addition, the results indicate an improvement in survival with successful EBVR procedure.
将单向阀置入肺部病变最严重的肺叶进行支气管内肺减容术(EBVR),是改善重度异质性肺气肿患者肺功能的一种非侵入性方法。问题在于选择合适的患者进行该手术。此外,大多数研究尚未报道其长期效果。
对35例重度致残性肺气肿患者进行EBVR,这些患者在CT上有一个放射学上明显增大(至少增大125%)的目标肺叶,且叶间裂清晰可见且完整。多数成功存活者随后被随访了五年。
5例(14%)为原发性失败(定义为第一秒用力呼气容积(FEV)增加少于15%),10例(28%)为继发性失败(瓣膜因某种原因咳出或取出)。在21例成功的患者中,FEV平均改善了59%。多年来,FEV逐渐下降,但5年后仍高于初始水平。在成功组中,76%的患者5年后仍存活,而在拒绝或失败组中这一比例仅为50%。
通过仔细挑选患者,可显著改善肺功能,且这些改善虽会缓慢下降,但能持续数年。此外,结果表明成功的EBVR手术可提高生存率。